Prostate Cancer

... Threshold Announces Management Additions Threshold Announces Management Additions Michael Brawer, M.D.

Appointed Head of Urology Therapeutic Area Clinical, Regulatory and Manufacturing Vice Presidents Added REDWOOD CITY, Calif., March 28 /PRNewswire-FirstCall/ - Threshold Pharmaceuticals, Inc.

(Nasdaq: THLD), today announced that Michael Brawer, M.D.

has been named Urology Therapeutic Area Head.

Dr.

Brawer joins Threshold as a member of the management team and will lead the strategic product development for TH-070, the Company's late-stage product candidate for Benign Prostatic Hyperplasia (BPH), and help to identify additional genitourinary opportunities for Threshold.

In addition, the Company noted that during the past year it had continued to strengthen its development capabilities with the addition of three vice presidents to help manage the Company's clinical development programs, which include two phase 3 studies.

Dr.

Brawer, a consultant to Threshold Pharmaceuticals since 2004, has been the director of the Northwest Prostate Institute in Seattle, Washington since 1998.

He was formerly Professor of Urology and adjunct Professor of Pathology at the University of Washington.

"We are extremely pleased with Michael's commitment to Threshold," said Alan Colowick, chief medical officer.

"His knowledge and depth of understanding of the urology area has provided a great deal of insight into the treatment of BPH and the importance of...

Read more...